Cardiology Medical News about Body Weight Fatty Acids, Omega-3 Triglycerides

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death

3. The Job Market for 2008-2009: Compensation

4. Renal Artery Stenosis

5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The Effect of Prescription Omega-3 Fatty Acids on Body Weight After 8 to 16 Weeks of Treatment for Very High Triglyceride Levels
Postgraduate Medicine, 09/30/09

Bays HE et al. – When coadministered with fenofibrate for up to 16 weeks, the modest daily caloric contribution of P–OM3 (Lovaza 4 g/day) did not alter body weight or waist circumference compared with baseline or compared with fenofibrate plus placebo in patients with very high triglyceride levels.

Methods

This analysis evaluated 167 dyslipidemic (triglycerides: >= 500 mg/dL and < 1300 mg/dL), overweight/obese (body mass index [BMI] >= 25 kg/m2 and <= 43 kg/m2) patients aged 18 to 79 years.
Data were derived from an 8–week, randomized, double–blinded, placebo–controlled, parallel–group trial comparing P–OM3 4 g/day + fenofibrate 130 mg/day (n = 84) versus placebo (4 g/day of corn oil) + fenofibrate 130 mg/day (n = 83), and an 8–week open–label extension (n = 117), during which all subjects received P–OM3 + fenofibrate.
Subjects who received P–OM3 + fenofibrate continued the same treatment in the extension phase (non–switchers; n = 59).
Those who initially received corn oil placebo + fenofibrate received P–OM3 + fenofibrate in the extension phase (switchers; n = 58).

Results

During the 8–week double–blind phase in subjects receiving fenofibrate, the addition of P–OM3 (versus placebo) did not significantly change median (minimum, maximum) body weight or waist circumference.
In the 8–week extension phase, non–switchers and switchers did not differ in median change from the end of the double–blind phase in body weight, or waist circumference.

<< Previous
Relation of Obesity to Heart Failure Hospitalization and...

Next >>
Incidence and predictors of silent myocardial infarction in type...